Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways